Isis Pharmaceuticals Inc., of Carlsbad, Calif., and Genzyme Corp., of Cambridge, Mass., a unit of Sanofi SA, reported two-year data from a Phase III long-term extension study showing that Kynamro (mipomersen) maintained robust reductions in LDL-C in patients, as well as reductions in all other Apo B-containing atherogenic lipoproteins measured, with a safety profile consistent with the Phase III studies.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter